Amphastar Pharmaceuticals, Inc.

Valuation Analysis

About the Company

Amphastar Pharmaceuticals, Inc. en bref

Amphastar Pharmaceuticals, Inc. (AMPH) is currently trading at 16,42 € with a market capitalization of 724 M €. The trailing P/E ratio stands at 11.33x, with a forward P/E of 5.99x. The 52-week range spans from 14,53 € to 27,28 €; the current price is 39.8% below the yearly high. Year-over-year revenue growth stands at +0.4%. The net profit margin stands at 11%.

💰 Dividende

Amphastar Pharmaceuticals, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

6 analystes évaluent Amphastar Pharmaceuticals, Inc. (AMPH) au consensus : None. L'objectif de cours moyen est de 19,92 €, soit un potentiel de +21.39% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 16,58 € à 26,18 €.

Amphastar Pharmaceuticals, Inc. : la thèse d'investissement en détail

Amphastar Pharmaceuticals, Inc. (AMPH) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Our valuation screen flags the stock as undervalued relative to its fundamentals — multiples are running below where the cash flow profile would normally justify.

Le scénario baissier

Revenue growth has slowed to just 0.4%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Short interest sits at 17.78% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

The EV/EBITDA multiple of 6.46x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The forward P/E of 5.99x is meaningfully below the trailing 11.33x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 21.39% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (17.78%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Amphastar Pharmaceuticals, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.